Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company working towards targeting kinase signaling and nuclear receptor pathways - A target class in treating Inflammation, Autoimmune, Cancer, and Neurodegenerative diseases. The Arrien Pharmaceuticals successfully applied and applying its proprietary platform FFDD technology and discovered a pipeline of uniquely positioned pre-clinical stage programs for future treatment of Multiples Sclerosis (MS), Psoriasis, Cancer (Ovarian, Breast, Prostate, DLBCL, and Lung), Rheumatoid Arthritis (RA), and Parkinson's Diseases.
Arrien Pharmaceuticals FFDD technology is a Fragment-Based Drug Design typically involves empirical and structural data input assisting our Medicinal Chemists in early phase of lead-to-drug-lead design process. Arrien Pharmaceuticals cost-competent approach rapidly aid our scientific team in selecting pre-clinical candidate ready compounds.
Arrien Pharmaceuticals most advanced program ARN-6039 successfully completed Phase 1 clinical trials late Q4 2016. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. A Phase 2 clinical POC studies for Psoriasis (oral and topical), Multiple Sclerosis and NMO (Neuromyelitis Optica) disease indications planed for Q2 2017.
Arrien Pharmaceuticals competitive and unique drug discovery approaches coupled with experienced scientific and management team with expertise in multidisciplinary areas of medicinal, biological and Clinical Sciences has been the key to company's technology and success since its incorporation in 2011.